Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker KBH
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Arthur Reginald Collins Director | KBH KB Home | Sale | 4,000 | $56.96 | $227.8K Sale | Form 4 ↗ |
| Aug 5, 2026 | Albert Z. Praw EVP, Real Estate & Bus. Dev. | KBH KB Home | Sale | 22,015 | $58.70 | $1.3M Sale | Form 4 ↗ |
| Jul 15, 2026 | Jeffrey T. Mezger Executive Chairman, Director | KBH KB Home | Sale | 30,008 | $56.70 | $1.7M Sale | Form 4 ↗ |
| Jul 15, 2026 | Jeffrey T. Mezger Executive Chairman, Director | KBH KB Home | Sale | 21,010 | $56.24 | $1.2M Sale | Form 4 ↗ |
| Jul 14, 2026 | Jeffrey T. Mezger Executive Chairman, Director | KBH KB Home | Sale | 39,204 | $55.45 | $2.2M Sale | Form 4 ↗ |
| Jul 14, 2026 | Jeffrey T. Mezger Executive Chairman, Director | KBH KB Home | Sale | 89,858 | $54.87 | $4.9M Sale | Form 4 ↗ |
| Jul 13, 2026 | Robert V. McGibney President and CEO, Director | KBH KB Home | Sale | 20,621 | $55.31 | $1.1M Sale | Form 4 ↗ |
| Jul 13, 2026 | Jeffrey T. Mezger Executive Chairman, Director | KBH KB Home | Sale | 12,825 | $55.81 | $715.8K Sale | Form 4 ↗ |
| Jul 13, 2026 | Jeffrey T. Mezger Executive Chairman, Director | KBH KB Home | Sale | 82,047 | $54.95 | $4.5M Sale | Form 4 ↗ |
| Nov 4, 2025 | Albert Z. Praw EVP, Real Estate & Bus. Dev. | KBH KB Home | Sale | 20,284 | $60.08 | $1.2M Sale | Form 4 ↗ |
| Jul 15, 2025 | Robert V. McGibney President and COO | KBH KB Home | Sale | 14,000 | $53.52 | $749.3K Sale | Form 4 ↗ |
| May 16, 2025 | Arthur Reginald Collins Director | KBH KB Home | Sale | 5,000 | $54.38 | $271.9K Sale | Form 4 ↗ |
| Jan 28, 2025 | Jeff Kaminski EVP & Chief Financial Officer | KBH KB Home | Sale | 1,028 | $69.41 | $71.4K Sale | Form 4 ↗ |
| Jan 28, 2025 | Jeff Kaminski EVP & Chief Financial Officer | KBH KB Home | Sale | 26,472 | $68.75 | $1.8M Sale | Form 4 ↗ |
| Nov 14, 2024 | Albert Z. Praw EVP, Real Estate & Bus. Dev. | KBH KB Home | Sale | 18,324 | $79.18 | $1.5M Sale | Form 4 ↗ |
| Oct 14, 2024 | Jeff Kaminski EVP & Chief Financial Officer | KBH KB Home | Sale | 27,500 | $79.40 | $2.2M Sale | Form 4 ↗ |
16 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:09 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances